7 assets in Renal Pelvis Carcinoma

Therapeutic assets addressing Renal Pelvis Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pembrolizumab Renal Pelvis Carcinoma	Alliance for Clinical Trials in Oncology	P3	B (60)
Tivozanib Renal Pelvis Carcinoma	Alliance for Clinical Trials in Oncology	P3	B (56)
Ipilimumab Renal Pelvis Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Nivolumab Renal Pelvis Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Tocilizumab Renal Pelvis Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
ly4052031 Renal Pelvis Carcinoma	Eli Lilly and Company	P1	CC (43)
ly4101174 Renal Pelvis Carcinoma	Eli Lilly and Company	P1	CC (43)